Home › Cytopenia › Washington
Cytopenia clinical trials in Washington, DC
5 studies for Cytopenia are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
CHIP/CCUS Natural History Protocol
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C.
- American Oncology Partners of Maryland, PA, Bethesda · 7 mi away
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
RecruitingPhase 2
- The Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda · 7 mi away
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
RecruitingObservational studyHealthy volunteers welcome
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Cytopenia trials in other cities
- Houston, TX4 studies
- Los Angeles, CA3 studies
- Boston, MA3 studies
- Seattle, WA3 studies
- Milwaukee, WI3 studies
- New York City, NY3 studies
- San Diego, CA3 studies
- Hot Springs, AR3 studies
- Philadelphia, PA3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.